ANRS, Emerging Infectious Diseases: Hepatitis C trials

The registry lists 30 Hepatitis C studies with ANRS, Emerging Infectious Diseases as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 10Phase 3 2Phase 4 2No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"Not yet recruitingNCT07412977
• Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard StrategyNot yet recruitingNCT07098481Phase 4
• Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruitingNCT05992077Not applicable
• Community Intervention to Eliminate HCV Among People Who Use Drugs.Active, not recruitingNCT05794646Not applicable
• Health and Migration Trajectories of Housekeepers in BamakoCompletedNCT05472051
• Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina FasoStatus unknownNCT04136405
• HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)Status unknownNCT04044586
• A Community-based Intervention Among Active Drug Users in MontpellierCompletedNCT04008927Not applicable
• Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in CambodiaCompletedNCT03992313Not applicable
• DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)CompletedNCT03537196Phase 4
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in EgyptStatus unknownNCT03510637
• Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCVCompletedNCT03324633
• PoC-HCV Genedrive Viral Detection Assay Validation StudyCompletedNCT02992184
• Investigative Mathematical Modeling of Hospital Transmission of Hepatitis CStatus unknownNCT02826447
• Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
• Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedNCT02405013Phase 2
• Qualification of Point-of-Care Assays for Management of HCV PatientsStatus unknownNCT02335320
• Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin RegimenWithdrawnNCT02309450Phase 2
• Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infectionCompletedNCT02125500Phase 2
• Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedNCT02107365Phase 2
• Evaluation of the National Treatment Program of Hepatitis C in EgyptWithdrawnNCT02101177
• Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
• Therapeutic Option for Hepatitis B and C: a French CohortStatus unknownNCT01953458
• Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
• French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and RibavirinCompletedNCT01514890
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT01010646Phase 2
• ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIVCompletedNCT00901524Phase 2
• Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.CompletedNCT00323804Phase 2/3
• Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) CoinfectionTerminatedNCT00158535Phase 2